Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (OTCPK:TSOI)

Fundamentals Snapshot (OTCPK:TSOI)

Current News (OTCPK:TSOI)

Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial

Business Wire 5 days ago

Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder

Business Wire 6 days ago

Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)

Business Wire 13 days ago

Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome

Business Wire August 29, 2022

Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome

Business Wire August 25, 2022

Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte(TM) on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches

Business Wire August 12, 2022

Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells

Business Wire July 28, 2022

Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell(TM) Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial

Business Wire July 18, 2022

John Hopkin's University Publishes Efficacy of QuadraMune(TM) Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

Business Wire May 27, 2022

Opinion & Analysis (OTCPK:TSOI)

No current opinion is available.

Bullboard Posts (OTCPK:TSOI)

Huge news!

Wow these guys never fail to impress. Todays news is further proof that these cellular medicines will be here to stay. From treating...
jefftrade11 - January 25, 2021

Interesting market here

I suppose I’ll go ahead and kick this board off. I’ve been taking neuenergy for the caffeine and pt since a hospitalization 3 years ago...
JuiceNewton - October 16, 2018